World First For Advicenne’s Rare Kidney Disease Drug On The Cards
ADV7103 Could Become The First Approved Treatment For Distal Renal Tubular Acidosis
Advicenne should soon find out whether the European Medicines Agency will give its product, ADV7103, the thumbs up. Approval then wouldn’t be far off.
You may also be interested in...
Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.
ViiV Healthcare’s “last resort” HIV drug, fostemsavir, is one of 16 new medicines that are up for an opinion by the European Medicines Agency on whether they should be authorized for use across the EU.
Having had a bid for accelerated assessment rejected by the EMA last year, the French biotech is getting a standard review for ADV7103 in dRTA patients and hopes to launch late 2020.